About
Gossamer Bio Inc (NASDAQ:GOSS) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 17 2026
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Feb 23 2026
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Jan 9 2026
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 24 2025
Gossamer Bio to Participate in Upcoming Investor Conferences
Nov 5 2025
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Financials
Revenue
$48.47 M
Market Cap
$86.84 M
EPS
-0.75
